Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis

被引：0
|
作者：
Thomas Wilke
Sabrina Mueller
Andreas Fuchs
Margit S. Kaltoft
Stefan Kipper
Malgorzata Cel
机构：
[1] Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM) an der Hochschule Wismar,Global Development
[2] Ingress-Health,undefined
[3] AOK PLUS,undefined
[4] Novo Nordisk A/S,undefined
[5] Novo Nordisk Pharma GmbH,undefined
[6] Novo Nordisk Region Europe,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Claims data; Cost; Effectiveness; Germany; Insulin; Liraglutide; Propensity score; Real-world; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2357 / 2370
页数：13
相关论文
共 50 条
  • [21] THE COST-EFFECTIVENESS OF DULAGLUTIDE VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN
    Lin, H.
    Babineaux, S.
    Lew, T.
    Lowin, J.
    Lovato, E.
    Strizek, A. A.
    Rajan, N.
    VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
  • [22] Effectiveness of simplified diabetes nutrition education on glycemic control and other diabetes-related outcomes in patients with type 2 diabetes mellitus
    Hashim, Saman Agad
    Yusof, Barakatun-Nisak Mohd
    Abu Saad, Hazizi
    Ismail, Suriani
    Hamdy, Osama
    Mansour, Abbas Ali
    CLINICAL NUTRITION ESPEN, 2021, 45 : 141 - 149
  • [23] Statins Can Delay Insulin Use and Reduce Diabetes-related Diseases in Asian Patients With Type 2 Diabetes
    Chen, Hsin-Hung
    Yeh, Chih-Jung
    Lin, Cheng-Li
    Yeh, Su-Yin
    Kao, Chia-Hung
    MEDICINE, 2015, 94 (17) : e735
  • [24] COST-EFFECTIVENESS OF LIRAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES IN THE SLOVAK REPUBLIC
    Ilavska, A.
    Uliciansky, V
    Wrona, W.
    Lacka, J.
    Czech, M.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A291
  • [25] Factors Associated with Diabetes-Related Distress in Type 2 Diabetes Mellitus Patients
    Bhaskara, Gilang
    Budhiarta, Anak Agung Gde
    Gotera, Wira
    Saraswati, Made Ratna
    Dwipayana, I. Made Pande
    Semadi, I. Made Siswadi
    Nugraha, Ida Bagus Aditya
    Wardani, Ida Ayu Kusuma
    Suastika, Ketut
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2022, 15 : 2077 - 2085
  • [26] A Retrospective Analysis of the Effect of Liraglutide in Asian Indian Patients With Type 2 Diabetes With Proteinuria
    Mohan, Viswanathan
    Kannan, A.
    Jebarani, S.
    DIABETES, 2012, 61 : A569 - A569
  • [27] Efficacy and Safety of Liraglutide in 195 Patients With Type 2 Diabetes in India: A Retrospective Analysis
    Kesavadev, Jothydev
    Shankar, Arun
    Gopalakrishnan, Gopikakrishnan
    Veeresh, Binushma
    Jothydev, Sunitha
    DIABETES, 2012, 61 : A605 - A606
  • [28] Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
    Ericsson, Asa
    Glah, Divina
    Lorenzi, Maria
    Jansen, Jeroen P.
    Fridhammar, Adam
    PLOS ONE, 2018, 13 (02):
  • [29] Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications
    Shao, Hui
    Shi, Lizheng
    Furman, Roy E.
    Meneghini, Luigi
    Harlan, Timothy S.
    Fonseca, Vivian
    DIABETES, 2019, 68
  • [30] LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS
    de Arellano Serna, Ramirez A.
    Mezquita-Raya, P.
    Vega-Hernandez, G.
    Wojcik, R.
    Schlueter, M.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
12345